Alcan Composites, a business unit of Alcan Inc., and Cyclics Europe GmbH (Germany), a subsidiary of Cyclics Corporation (USA) have today announced a cooperation agreement for the development and commercialization of Cyclics’ CBT® resin, the cyclic form of polybutylene terephthalate resin, in key strategic markets. CBT® resin is an innovative plastic that allows new material combinations for the composites industry. Specific terms of the agreement were not disclosed.
Cyclics, the manufacturer of CBT® resin, has granted a global exclusivity to Alcan Composites for the marketing and sales activities for CBT® resin based composite materials targeting display and graphic arts, architecture markets, as well as general industry infrastructure applications. “CBT® resin with its unique characteristics will enable a considerable improvement to both process productivity and product performance, making it a very attractive new semi-finished material for future applications”, says Georg Reif, president of Alcan Composites.
“Our alliance with Alcan Composites helps us deliver our unique plastic resins to the architecture, construction and general industry infrastructure markets,” said Roman Eder, Managing Director, Cyclics GmbH. “Alcan Composites brings world class expertise in manufacturing technology and market access via their global distribution network.”
Cyclics Corporation, headquartered in Schenectady, New York, manufactures innovative plastics, based on technology developed and patented by GE, that offer breakthroughs in processing, making new products possible and changing the economics of existing ones. Cyclics has an alliance with Dow Automotive to develop CBT® resins for automotive applications. The water-like processing viscosities of Cyclics’ engineering thermoplastic products offer improvements in performance and productivity for structural composites, compounding, casting and rotational molding.
For more information on polybutylene terephthalate, click here.